Table 3 Survival analysis of cervical cancer patients who underwent primary pelvic exenteration
From: Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer
Primary pelvic exenteration in advanced cervical cancer | |||
|---|---|---|---|
Median (months) | IQR | P value | |
Squamous cell carcinoma (n = 4) | 47.6 | 8.0-70.9 | 0.26 |
Adenocarcinoma (n = 8) | 13.5 | 10.1-19.8 | |
Vaginal fistula | |||
Absent (n = 7) | 12.9 | 8.2-16.4 | 0.09 |
Present (n = 5) | 22.5 | 9.4-62.9 | |
Severe adverse events | |||
Severe adverse events (n = 3) | 19.1 | 7.4-86.7* | 0.33 |
No severe adverse events (n = 9) | 12.7 | 9.3-18.5 | |
Specimen margins status | |||
Positive margins (n = 2) | 12.7 | 12.9-14.1* | 0.77 |
Negative margins (n = 10) | 13.5 | 8.2-30.5 | |
Lymph node metastases | |||
Absent (n = 8) | 17.2 | 11.2-22.4 | 0.79 |
Present (n = 4) | 11.9 | 7.0-24.4 | |